Melanoma antigen recognized by T cells 1-derived peptide–Human leukocyte antigen class II complex (MART-1–HLA class II complex)

The Melanoma antigen recognized by T cells 1 (MART-1)-derived peptide–Human leukocyte antigen (HLA) class II complex is a molecular assembly consisting of a processed MART-1 peptide fragment bound within the groove of an HLA class II molecule (UniProt Q16655). MART-1, also known as Melan-A, is a lineage-specific differentiation antigen expressed predominantly in melanocytes and melanoma cells, making it a primary target for cancer immunotherapy (PubMed: 8164633). While MART-1 is widely recognized for its presentation on HLA class I molecules to CD8+ cytotoxic T cells, its presentation on HLA class II molecules (such as HLA-DR, HLA-DQ, or HLA-DP) is essential for the activation of CD4+ helper T cells (Zarour et al., 2000). These CD4+ T cells are critical for maintaining long-term anti-tumor immunity, providing necessary cytokines for CD8+ T cell survival, and in some cases, exerting direct cytotoxic activity against tumor cells (PubMed: 12414648). Therapeutic interventions targeting this complex include long peptide vaccines and T-cell receptor (TCR) engineered therapies that aim to recruit the helper arm of the immune system to the tumor microenvironment (ClinicalTrials.gov). Clinical challenges associated with targeting this complex include the potential for on-target, off-tumor toxicity, as MART-1 is also expressed in normal melanocytes found in the skin, retina, and inner ear (PubMed: 19380631). Consequently, patients treated with MART-1-directed therapies may develop autoimmune-like conditions such as vitiligo, uveitis, or hearing loss (PubMed: 15150569).

Other names

Melan-A–HLA class II complexMART-1–MHC class II complexMelan-A peptide–HLA-DR complexMART-1 peptide–HLA-DQ complexMART-1 peptide–HLA-DP complex

The complex acts as a specific ligand for T-cell receptors (TCRs) on CD4+ T lymphocytes, initiating an adaptive immune response against MART-1-expressing cells.